About this ingredient
Orforglipron is an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. It acts on GLP-1 receptors involved in appetite regulation, satiety, and blood glucose control. In the United States, it was approved in April 2026 under the brand name Foundayo for long-term weight reduction and weight maintenance in eligible adults with obesity or overweight accompanied by at least one weight-related medical condition. Its use is intended to be combined with a reduced-calorie diet and increased physical activity. Orforglipron is a prescription medicine, not a dietary supplement, and it may cause significant adverse effects. Approval and availability can differ between countries, so its regulatory status in Pakistan should be confirmed with the Drug Regulatory Authority of Pakistan (DRAP) or a qualified healthcare professional before considering its use.